BE2017C027I2 - - Google Patents

Download PDF

Info

Publication number
BE2017C027I2
BE2017C027I2 BE2017C027C BE2017C027C BE2017C027I2 BE 2017C027 I2 BE2017C027 I2 BE 2017C027I2 BE 2017C027 C BE2017C027 C BE 2017C027C BE 2017C027 C BE2017C027 C BE 2017C027C BE 2017C027 I2 BE2017C027 I2 BE 2017C027I2
Authority
BE
Belgium
Application number
BE2017C027C
Other languages
French (fr)
Original Assignee
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Biopharm Ltd filed Critical Ipsen Biopharm Ltd
Publication of BE2017C027I2 publication Critical patent/BE2017C027I2/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0002General or multifunctional contrast agents, e.g. chelated agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032Methine dyes, e.g. cyanine dyes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806Suspensions, emulsions, colloids, dispersions
    • A61K49/1812Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0085Brain, e.g. brain implants; Spinal cord
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1277Processes for preparing; Proliposomes
    • A61K9/1278Post-loading, e.g. by ion or pH gradient

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BE2017C027C 2004-05-03 2017-07-10 BE2017C027I2 (US06903085-20050607-C00075.png)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56792104P 2004-05-03 2004-05-03
US11/601,451 US8658203B2 (en) 2004-05-03 2006-11-17 Liposomes useful for drug delivery to the brain

Publications (1)

Publication Number Publication Date
BE2017C027I2 true BE2017C027I2 (US06903085-20050607-C00075.png) 2024-08-08

Family

ID=46045566

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2017C027C BE2017C027I2 (US06903085-20050607-C00075.png) 2004-05-03 2017-07-10

Country Status (2)

Country Link
US (3) US8658203B2 (US06903085-20050607-C00075.png)
BE (1) BE2017C027I2 (US06903085-20050607-C00075.png)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101462819B1 (ko) * 2004-05-03 2014-11-21 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
ES2594621T3 (es) * 2004-06-01 2016-12-21 Kabushiki Kaisha Yakult Honsha Preparación de irinotecán
SI1807009T1 (sl) * 2004-10-05 2015-04-30 Genzyme Corporation Stopničasta kanila
CA2619882C (en) 2005-08-23 2015-05-26 The Regents Of The University Of California Reflux resistant cannula and system for chronic delivery of therapeutic agents using convection-enhanced delivery
US20140335166A1 (en) * 2013-05-08 2014-11-13 Michael W. Fountain Methods of Making and Using Nano Scale Particles
US20080305157A1 (en) * 2007-06-08 2008-12-11 University Of Maryland Office Of Technology Commercialization Encapsulation and separation of charged organic solutes inside catanionic vesicles
WO2009033176A1 (en) * 2007-09-07 2009-03-12 The Trustees Of The University Of Pennsylvania A method of targeting a transferrin receptor
EP2959917A3 (en) 2007-10-19 2016-02-24 The Regents of The University of California Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss
WO2009073698A1 (en) * 2007-12-04 2009-06-11 Bracco Imaging S.P.A. Homogenization of a radiopharmaceutical using sonification and/or rotor-stator technology to produce a homogenous suspension, emulsion, mixture or solid suspension of immiscible ingredients
AR076634A1 (es) * 2008-11-21 2011-06-29 Medgenesis Therapeutix Inc Composiciones y metodo para tratar desordenes del sistema nervioso central
JP5588619B2 (ja) * 2009-03-11 2014-09-10 一丸ファルコス株式会社 pH応答性リポソーム
DE102009031274A1 (de) * 2009-06-30 2011-01-13 Justus-Liebig-Universität Giessen Liposomen zur pulmonalen Applikation
US10105485B2 (en) 2010-04-16 2018-10-23 MRI Interventions, Inc. MRI surgical systems including MRI-compatible surgical cannulae for transferring a substance to and/or from a patient
CN107261110A (zh) * 2010-06-19 2017-10-20 健康科学西部大学 Peg化脂质体包封的糖肽抗生素的新制剂
CN103370059A (zh) * 2010-11-26 2013-10-23 约翰内斯堡威特沃特斯兰德大学 一种药物递送装置
US10980798B2 (en) * 2011-11-03 2021-04-20 Taiwan Liposome Company, Ltd. Pharmaceutical compositions of hydrophobic camptothecin derivatives
PL2814513T3 (pl) 2012-02-14 2018-06-29 The Regents Of The University Of California Układowe dostarczanie i regulowana ekspresja genów parakrynnych w chorobach sercowo-naczyniowych i innych stanach
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US20150306236A1 (en) * 2012-09-04 2015-10-29 Lauren Sciences Llc Bolaamphiphilic compounds, compositions and uses thereof
EP2892509A4 (en) * 2012-09-04 2016-05-18 Lauren Sciences Llc BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF
EP2948132B1 (en) * 2013-01-24 2020-08-19 Memorial Sloan Kettering Cancer Center Method for diagnosing or treating tumors using sphingomyelin containing liposomes
KR102554628B1 (ko) 2013-02-01 2023-07-12 존원 파마, 인코포레이티드 리포좀 내로 난수용성 약물의 원격 부하
US9289502B2 (en) 2013-03-08 2016-03-22 Emerald Therapeutics, Inc. Preparation of oligo conjugates
WO2014179760A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
US9891296B2 (en) 2013-09-13 2018-02-13 MRI Interventions, Inc. Intrabody fluid transfer devices, systems and methods
US20170182129A1 (en) 2014-04-03 2017-06-29 The Regents Of The University Of California Systemic delivery of virus vectors encoding urocortin-2 and related genes to treat diabetes-related cardiac dysfunctions and congestive heart failure
EP3177269A4 (en) 2014-08-04 2018-02-28 Zoneone Pharma, Inc. Remote loading of sparingly water-soluble drugs into lipid vesicles
US20160158154A1 (en) * 2014-12-05 2016-06-09 Georgia Tech Research Corporation Protein vesicles and methods of making and using thereof
WO2016094402A1 (en) 2014-12-09 2016-06-16 Merrimack Pharmaceuticals, Inc. Treatment of breast cancer with liposomal irinotecan
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
CA2992789A1 (en) 2015-08-20 2017-02-23 Ipsen Biopharm Ltd. Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
JP2018528185A (ja) 2015-08-21 2018-09-27 イプセン バイオファーム リミティド リポソーム型イリノテカン及びオキサリプラチンを含む組み合わせ療法を使用して転移性膵臓癌を治療するための方法
EP3337457A4 (en) * 2015-08-21 2019-01-02 University of Otago Acoustic driven drug delivery systems
US10123969B2 (en) 2015-10-15 2018-11-13 Wisconsin Alumni Research Foundation Osmotic enhancement of drug/therapeutic delivery to the brain following infusion or injection into the cerebrospinal fluid
US10456360B2 (en) * 2015-10-16 2019-10-29 Ipsen Biopharm Ltd. Stabilizing camptothecin pharmaceutical compositions
PL3386527T3 (pl) 2015-12-10 2022-01-31 The Regents Of The University Of California Kompozycje do zastosowania w leczeniu lub łagodzeniu neurozapalenia, neurodegeneracji, bólu neuropatycznego i migreny
EP3393571B1 (en) 2016-02-17 2024-03-06 ClearPoint Neuro, Inc. Intrabody surgical fluid transfer assemblies with adjustable exposed cannula to needle tip length, related systems and methods
MA46709A (fr) 2016-11-02 2019-09-11 Ipsen Biopharm Ltd Traitement du cancer gastrique au moyen de polythérapies comprenant de l'oxaliplatine, du 5-fluoruracile (et de la leucovorine) et de l'irinotécan sous forme liposomale
US10391154B2 (en) 2017-07-19 2019-08-27 Leadiant Biosciences Ltd. Compositions and methods for treating or ameliorating fibrosis, systemic sclerosis and scleroderma
JP6297737B1 (ja) * 2017-09-25 2018-03-20 ジェイ−ネットワーク,インコーポレイテッド 正に帯電した荷電ニオソームの調製方法及び荷電ニオソーム
US20210113595A1 (en) * 2018-04-30 2021-04-22 Purdue Research Foundation Liposomal nano formulation of combinational antibiotics and the uses thereof
EP3781074A1 (en) 2018-05-09 2021-02-24 ClearPoint Neuro, Inc. Mri compatible intrabody fluid transfer systems and related devices and methods
US11253237B2 (en) 2018-05-09 2022-02-22 Clearpoint Neuro, Inc. MRI compatible intrabody fluid transfer systems and related devices and methods
ES2949701T3 (es) 2018-07-26 2023-10-02 Cvie Therapeutics Ltd Compuestos similares al 17beta-heterociclil-digitalis para el tratamiento de la insuficiencia cardíaca
WO2020102323A1 (en) * 2018-11-14 2020-05-22 Taiwan Liposome Co., Ltd. Sustained-release pharmaceutical compositions comprising a therapeutic agent for treating diseases due to reduced bone density or cartilage loss and uses thereof
CN113474360A (zh) 2019-02-18 2021-10-01 伊莱利利公司 治疗性抗体制剂
CN112118846B (zh) 2019-03-05 2024-04-16 风树疗法公司 治疗急性心力衰竭(ahf)用的含伊司他肟的静脉内制剂
US11684750B2 (en) 2019-10-08 2023-06-27 Clearpoint Neuro, Inc. Extension tube assembly and related medical fluid transfer systems and methods
EP3805243B1 (en) 2019-10-09 2023-11-15 Windtree Therapeutics, Inc. Androstane derivatives with activity as pure or predominantly pure stimulators of serca2a for the treatment of heart failure
CN117083381A (zh) 2021-03-18 2023-11-17 加州大学董事会 用于靶向炎性细胞或活化细胞和治疗或改善炎性病症和疼痛的组合物和方法
WO2023004113A2 (en) 2021-07-22 2023-01-26 The Regents Of The University Of California Compositions and methods for using purified human rna editing enzymes
WO2023118893A1 (en) * 2021-12-22 2023-06-29 Mycural Therapeutics Novel pyridocarbazolium compounds and medical uses thereof
CN116731010A (zh) * 2023-06-08 2023-09-12 西南大学 长春胺类衍生物及其制备方法和应用

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US578987A (en) * 1897-03-16 Mechanism for propelling vessels
DE2740053A1 (de) 1977-09-06 1979-05-03 Klaus Prof Dr Med Gersonde Verwendung von allosterischen effektoren mit hilfe von lipidvesikeln ueber eine irreversible inkorporierung zwecks verbesserter o tief 2 -entladung des haemoglobins in erythrozyten
US4192869A (en) 1977-09-06 1980-03-11 Studiengesellschaft Kohle Mbh. Controlled improvement of the O2 release by intact erythrocytes with lipid vesicles
US4397846A (en) 1981-05-15 1983-08-09 Murray Weiner Storage-stable lipid vesicles and method of preparation
US5059591B1 (en) * 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity
US4649155A (en) 1983-07-22 1987-03-10 Hoffmann-La Roche Inc. Injectable solutions
US5736155A (en) 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
MX9203808A (es) * 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5043165A (en) * 1988-12-14 1991-08-27 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs
US4960790A (en) 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
ZA902710B (en) 1989-05-22 1991-12-24 Univ Georgia Res Found Enzyme luminescence assay
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
PL296382A1 (en) 1991-02-02 1993-11-02 Nika Health Products Ltd Li Li Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system
US5498420A (en) 1991-04-12 1996-03-12 Merz & Co. Gmbh & Co. Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions
DK0592446T3 (da) 1991-07-03 1996-01-29 Nexstar Pharmaceuticals Inc Fyldningsteknik til fremstilling af lægemiddelholdige liposomer
US5281237A (en) 1992-09-25 1994-01-25 Gimpelson Richard J Surgical stitching device and method of use
US6350853B1 (en) * 1993-04-26 2002-02-26 Peter E. Nielsen Conjugated peptide nucleic acids having enhanced cellular uptake
DE4320597A1 (de) 1993-06-22 1995-01-05 Heinz C Prof Dr Dr Schroeder Verwendung von Polyphosphaten zur antiviralen Therapie und als Immunmodulatoren
US6743917B2 (en) 1993-06-30 2004-06-01 University Of Pittsburgh Camptothecin analogs and methods of preparation thereof
US5534241A (en) * 1993-07-23 1996-07-09 Torchilin; Vladimir P. Amphipathic polychelating compounds and methods of use
US5538954A (en) 1994-06-24 1996-07-23 A/S Dumex (Dumex Ltd.) Salts of tetracyclines
DE69528355T2 (de) * 1994-02-04 2003-05-15 Lipocore Holding Ab Stockholm Doppelschicht-zusammensetzungen aus digalactosyldiacylglycerol enthaltendem galactolipid
US5783568A (en) 1994-06-10 1998-07-21 Sugen, Inc. Methods for treating cancer and other cell proliferative diseases
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
AU4981896A (en) 1995-02-14 1996-09-04 Sequus Pharmaceuticals, Inc. Liposome composition and method for administering liposome-loadable drugs
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
DE19605024A1 (de) 1996-01-31 1997-08-07 Schering Ag Neue selektive Taxane, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
DE69730218D1 (de) 1996-04-11 2004-09-16 Univ British Columbia Fusogene liposomen
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
CA2269758C (en) 1996-10-22 2008-01-08 Hermes Biosciences, Inc. Liposome compositions comprising ionizable compounds in stable precipitated form and methods for their preparation
US6210707B1 (en) 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
JP2000516641A (ja) 1997-07-02 2000-12-12 エスディージー インコーポレイテッド 診断および治療用途の目標指向性リポソーム構成物
US6316612B1 (en) 1997-08-22 2001-11-13 Ribozyme Pharmaceuticals, Inc. Xylofuranosly-containing nucleoside phosphoramidites and polynucleotides
US6083923A (en) 1997-10-31 2000-07-04 Isis Pharmaceuticals Inc. Liposomal oligonucleotide compositions for modulating RAS gene expression
RU2130771C1 (ru) 1998-06-01 1999-05-27 Автушенко Сергей Сергеевич Способ получения липосомальных препаратов
US6726925B1 (en) 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
AU1678900A (en) 1998-08-11 2000-03-06 All India Institute Of Medical Sciences A novel liposomal formulation useful in treatment of cancer and other proliferation diseases
DE69935435T2 (de) 1998-08-12 2007-12-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Mittels Ammoniumsulfatgradient hergestellte liposomale analgetische Zusammensetzungen
JP2002527466A (ja) * 1998-09-16 2002-08-27 アルザ・コーポレーション リポソーム−閉込めトポイソメラーゼ阻害剤
US6291676B1 (en) 1999-03-03 2001-09-18 University Of Kentucky Research Foundation Water-soluble derivatives of camptothecin/homocamptothecin
US7311924B2 (en) 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
CA2371483A1 (en) 1999-04-29 2000-11-09 Luke S. Guo Liposome compositions for improved drug retention
US20020049176A1 (en) * 1999-11-10 2002-04-25 Anderson Christen M. Modulation of mitochondrial mass and function for the treatment of diseases and for target and drug discovery
ES2272496T3 (es) 2000-02-04 2007-05-01 Lipoxen Technologies Limited Procedimiento de deshidratacion/rehidritacion para la preparacion de lipososmas.
EP1286671B1 (en) 2000-05-15 2006-04-05 Celgene Corporation Compositions for the treatment of colorectal cancer comprising thalidomide and irinotecan
US6486320B2 (en) 2000-09-15 2002-11-26 Aventis Pharma S.A. Preparation of camptothecin and of its derivatives
WO2002036073A2 (en) 2000-11-02 2002-05-10 Smithkline Beecham Corporation Receptor antagonist-lipid conjugates and delivery vehicles containing same
CA2442261A1 (en) 2001-03-26 2002-10-03 Alza Corporation Liposome composition for improved intracellular delivery of a therapeutic agent
WO2003030864A1 (en) 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
JP4822666B2 (ja) 2001-10-03 2011-11-24 セレーター ファーマシューティカルズ インコーポレイテッド 金属イオンをローディングするリポソーム
US20030129224A1 (en) 2001-11-13 2003-07-10 Paul Tardi Lipid carrier compositions and methods for improved drug retention
US20030220284A1 (en) * 2002-02-22 2003-11-27 Patricia Yotnda Delivery of adenoviral DNA in a liposomal formulation for treatment of disease
WO2003092700A1 (en) 2002-04-29 2003-11-13 Gmp Oxycell, Inc. Inositol pyrophosphates, and methods of use thereof
DK1519714T3 (da) 2002-06-28 2011-01-31 Protiva Biotherapeutics Inc Fremgangsmåde og apparat til fremstilling af liposomer
US20040243101A1 (en) * 2002-07-02 2004-12-02 Gillis Edward M. Minimally invasive drug delivery catheter
WO2004035032A2 (en) 2002-08-20 2004-04-29 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
US20040170677A1 (en) 2002-11-26 2004-09-02 Ning Hu Method of drug loading in liposomes by gradient
US20060222694A1 (en) 2003-06-27 2006-10-05 Oh Choon K Stabilized topotecan liposomal composition and methods
CA2530224A1 (en) 2003-07-09 2005-02-24 California Pacific Medical Center Remote detection of substance delivery to cells
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
KR101462819B1 (ko) 2004-05-03 2014-11-21 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
SI1807009T1 (sl) 2004-10-05 2015-04-30 Genzyme Corporation Stopničasta kanila
US20060129126A1 (en) * 2004-11-19 2006-06-15 Kaplitt Michael G Infusion device and method for infusing material into the brain of a patient
DK2377546T3 (en) * 2004-12-21 2017-02-13 Musc Found For Res Dev Compositions and Methods to Promote Wound Healing and Tissue Regeneration

Also Published As

Publication number Publication date
US9737528B2 (en) 2017-08-22
US8658203B2 (en) 2014-02-25
US20140127136A1 (en) 2014-05-08
US20070110798A1 (en) 2007-05-17
US20170035749A1 (en) 2017-02-09

Similar Documents

Publication Publication Date Title
BE2019C540I2 (US06903085-20050607-C00075.png)
BE2019C548I2 (US06903085-20050607-C00075.png)
BE2018C045I2 (US06903085-20050607-C00075.png)
BE2017C027I2 (US06903085-20050607-C00075.png)
BE2017C023I2 (US06903085-20050607-C00075.png)
BE2017C002I2 (US06903085-20050607-C00075.png)
BE2016C067I2 (US06903085-20050607-C00075.png)
BE2015C041I2 (US06903085-20050607-C00075.png)
BE2015C038I2 (US06903085-20050607-C00075.png)
BE2015C014I2 (US06903085-20050607-C00075.png)
BE2014C071I2 (US06903085-20050607-C00075.png)
BE2014C063I2 (US06903085-20050607-C00075.png)
BE2019C535I2 (US06903085-20050607-C00075.png)
BE2014C010I2 (US06903085-20050607-C00075.png)
BE2013C071I2 (US06903085-20050607-C00075.png)
BE2013C021I2 (US06903085-20050607-C00075.png)
BE2012C025I2 (US06903085-20050607-C00075.png)
BRPI0508002A (US06903085-20050607-C00075.png)
JP2005352782A5 (US06903085-20050607-C00075.png)
BE2016C042I2 (US06903085-20050607-C00075.png)
BE2015C012I2 (US06903085-20050607-C00075.png)
BE2015C033I2 (US06903085-20050607-C00075.png)
BE2015C011I2 (US06903085-20050607-C00075.png)
BE2014C002I2 (US06903085-20050607-C00075.png)
JP2004358243A5 (US06903085-20050607-C00075.png)